Patents by Inventor Edward J. Olhava

Edward J. Olhava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carbocycle-Substituted Purine And 7-Deazapurine Compounds
    Publication number: 20130338173
    Abstract: The present invention relates to carbocycle-substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 5, 2011
    Publication date: December 19, 2013
    Applicant: EPIZYME, INC.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz
  • Proteasome Inhibitors
    Publication number: 20130331595
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Proteasome Inhibitors
    Publication number: 20130331356
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Proteasome inhibitors
    Patent number: 8530694
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: September 10, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 8481550
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20130165457
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 19, 2012
    Publication date: June 27, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Steven P. Langston, Edward J. Olhava, Stepan Vyskocil
  • INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20120258927
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: Millenium Pharmaceuticals, Inc.
    Inventors: Steven P. Langston, Edward J. Olhava, Stepan Vyskocil
  • INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20120258977
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Steven P. Langston, Edward J. Olhava, Stepan Vyskocil
  • Inhibitors of E1 activating enzymes
    Patent number: 8207177
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: June 26, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Steven P. Langston, Edward J. Olhava, Stepan Vyskocil
  • Substituted Purine And 7-Deazapurine Compounds
    Publication number: 20120142625
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 2, 2011
    Publication date: June 7, 2012
    Applicant: EPIZYME, INC.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott R. Daigle
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20120071482
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 22, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • PROTEASOME INHIBITORS
    Publication number: 20110301124
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 8, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 8008307
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: August 30, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Proteasome inhibitors
    Patent number: 8003819
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: August 23, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20110136834
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 9, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen Critchley, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
  • Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
    Patent number: 7951810
    Abstract: This invention relates to compounds of formula (I-A) wherein Ring A and the variables X, Y, R3a, R3b, R3c, R3d, R4, R5, R5?, and m are defined herein. The compounds of formula (I-A) inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds of the invention are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: May 31, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen Critchley, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
  • Proteasome inhibitors
    Patent number: 7838673
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: November 23, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • PROTEASOME INHIBITORS
    Publication number: 20100204180
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: February 12, 2010
    Publication date: August 12, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Proteasome inhibitors
    Patent number: 7687662
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: March 30, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca
  • Proteasome inhibitors
    Publication number: 20090099132
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edward J. Olhava, Mihaela Diana Danca